Form 4: Immunovant CFO Sells Shares to Cover Tax Obligations

Eva Renee Barnett, CFO of Immunovant, Inc., sold 3,271 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On October 16, 2024, Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., sold 3,271 shares of Immunovant's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of 5,479 restricted stock units (RSUs) on October 12, 2024.
• The shares were sold at a weighted average price of $28.79, with individual transactions ranging from $28.31 to $29.14 per share.
• Following the transaction, Barnett directly owns 335,343 shares of Immunovant common stock.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction, indicating it was not a discretionary sale by Barnett.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sell to cover taxes on vested RSUs) and doesn't provide strong positive or negative signals about the company's prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives. This transaction is not necessarily indicative of the CFO's sentiment towards the company's future prospects.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• Upon vesting, these RSUs are subject to income tax, and executives often sell a portion of the shares to cover these tax liabilities.
• The 'sell to cover' practice is a standard method for managing these tax obligations, similar to practices at companies like Regeneron, Amgen, and Biogen.

Key Dates